Want to see AU:ACL full AI Analyst Report?
Total Valuation
Australian Clinical Labs Ltd has a market cap or net worth of AU$525.98M. The enterprise value is AU$741.17.
Market CapAU$525.98M
Enterprise ValueAU$741.17
Share Statistics
Australian Clinical Labs Ltd has 186,518,980 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding186,518,980
Owned by Insiders0.06%
Owned by Institutions―
Financial Efficiency
Australian Clinical Labs Ltd’s return on equity (ROE) is 0.16 and return on invested capital (ROIC) is 8.04%.
Return on Equity (ROE)0.16
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)8.04%
Return on Capital Employed (ROCE)0.16
Revenue Per Employee162.12K
Profits Per Employee5.27K
Employee Count4,500
Asset Turnover1.23
Inventory Turnover40.66
Valuation Ratios
The current PE Ratio of Australian Clinical Labs Ltd is 22.4. Australian Clinical Labs Ltd’s PEG ratio is -0.63.
PE Ratio22.4
PS Ratio0.59
PB Ratio2.87
Price to Fair Value2.87
Price to FCF2.79
Price to Operating Cash Flow3.24
PEG Ratio-0.63
Income Statement
In the last 12 months, Australian Clinical Labs Ltd had revenue of 729.52M and earned 23.71M in profits. Earnings per share was 0.12.
Revenue729.52M
Gross Profit150.21M
Operating Income61.49M
Pretax Income37.39M
Net Income23.71M
EBITDA196.84M
Earnings Per Share (EPS)0.12
Cash Flow
In the last 12 months, operating cash flow was 163.31M and capital expenditures -9.58M, giving a free cash flow of 153.73M billion.
Operating Cash Flow163.31M
Free Cash Flow153.73M
Free Cash Flow per Share0.82
Dividends & Yields
Australian Clinical Labs Ltd pays an annual dividend of AU$0.092, resulting in a dividend yield of 4.69%
Dividend Per ShareAU$0.092
Dividend Yield4.69%
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.85
52-Week Price Change19.50%
50-Day Moving Average2.58
200-Day Moving Average2.27
Relative Strength Index (RSI)52.88
Average Volume (3m)905.63K
Important Dates
Australian Clinical Labs Ltd upcoming earnings date is Feb 23, 2027, TBA (Confirmed).
Last Earnings DateAug 16, 2026
Next Earnings DateFeb 23, 2027
Ex-Dividend Date―
Financial Position
Australian Clinical Labs Ltd as a current ratio of 0.54, with Debt / Equity ratio of 225.66%
Current Ratio0.54
Quick Ratio0.47
Debt to Market Cap0.40
Net Debt to EBITDA1.59
Interest Coverage Ratio3.33
Taxes
In the past 12 months, Australian Clinical Labs Ltd has paid 13.38M in taxes.
Income Tax13.38M
Effective Tax Rate0.36
Enterprise Valuation
Australian Clinical Labs Ltd EV to EBITDA ratio is 3.77, with an EV/FCF ratio of 4.83.
EV to Sales1.02
EV to EBITDA3.77
EV to Free Cash Flow4.83
EV to Operating Cash Flow4.55
Balance Sheet
Australian Clinical Labs Ltd has AU$25.66M in cash and marketable securities with AU$337.40M in debt, giving a net cash position of -AU$311.75M billion.
Cash & Marketable SecuritiesAU$25.66M
Total DebtAU$337.40M
Net Cash-AU$311.75M
Net Cash Per Share-AU$1.67
Tangible Book Value Per Share-AU$0.08
Margins
Gross margin is 20.59%, with operating margin of 8.43%, and net profit margin of 3.25%.
Gross Margin20.59%
Operating Margin8.43%
Pretax Margin5.13%
Net Profit Margin3.25%
EBITDA Margin26.98%
EBIT Margin8.43%
Analyst Forecast
The average price target for Australian Clinical Labs Ltd is AU$2.45, which is 11.43% higher than the current price. The consensus rating is Hold
Price TargetAU$2.45
Price Target Upside-17.68% Downside
Analyst ConsensusHold
Analyst Count4
Revenue Growth Forecast-0.90%
EPS Growth Forecast-25.09%